PMID- 28860823
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 10
DP  - 2017
TI  - Survival significance of epidermal growth factor receptor tyrosine kinase 
      inhibitors and current staging system for survival after recurrence in patients 
      with completely resected lung adenocarcinoma.
PG  - 4135-4141
LID - 10.2147/OTT.S136569 [doi]
AB  - OBJECTIVE: We previously reported that the staging system and epidermal growth 
      factor receptor (EGFR) mutation status are key factors for treatment strategy and 
      predicting survival. However, the significance of these factors as predictors of 
      overall survival (OS) and postoperative recurrence survival (PRS) has not been 
      sufficiently elucidated. The objective here was to investigate EGFR mutation 
      status and p-stage, which affect PRS and OS in patients with completely resected 
      lung adenocarcinoma, using a different database. PATIENTS AND METHODS: We 
      retrospectively reviewed 56 consecutive lung adenocarcinoma patients with disease 
      recurrence in St. Marianna University Hospital between January 2010 and December 
      2014. RESULTS: EGFR mutants (M) were detected in 16/56 patients (29%). The 
      patients with EGFR M had a better OS than those with EGFR wild-type (WT) status 
      (5-year survival: 50.3% vs 43.1, P=0.133). There was no significant difference in 
      the 3-year recurrence-free survival rate between patients with M and WT (6.3% vs 
      7.7%, P=0.656), and the patients with EGFR M had a significantly better 3-year 
      PRS than those with WT (77.4% vs 51.7%, P=0.033). The 3-year PRS rate for 
      patients with M/pathologic stage (p-stage) I-II (87.5%) was better than that for 
      patients with M/p-stage III (60.0%), WT/p-stage I-II (52.7%), and WT/p-stage III 
      (43.8%). There was a significant difference between patients with M/p-stage I and 
      WT/p-stage I-II or WT/p-stage III (P=0.021 and 0.030, respectively). During the 
      study period, of the 16 patients with mutants, 12 patients (75%) received 
      EGFR-tyrosine kinase inhibitor (TKI) therapy and among the 40 patients with WT, 
      no patient received EGFR-TKI therapy. Multivariate survival analysis showed that 
      patients with EGFR-TKI therapy had a statistically significant association with 
      favorable PRS (hazard ratio 0.271; 95% confidence interval 0.074-1.000; P=0.050). 
      CONCLUSION: EGFR status and p-stage were found to be essential prognostic factors 
      for estimating PRS using this database. The recurrent patients with EGFR M and 
      EGFR-TKI therapy had a statistically significant association with favorable PRS.
FAU - Saji, Hisashi
AU  - Saji H
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
AD  - Department of Thoracic Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Sakai, Hiroki
AU  - Sakai H
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
FAU - Kimura, Hiroyuki
AU  - Kimura H
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
FAU - Miyazawa, Tomoyuki
AU  - Miyazawa T
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
FAU - Marushima, Hideki
AU  - Marushima H
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
FAU - Nakamura, Haruhiko
AU  - Nakamura H
AD  - Department of Chest Surgery, St Marianna University School of Medicine, 
      Miyamae-ku, Kawasaki, Kanagawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170821
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5571845
OTO - NOTNLM
OT  - EGFR
OT  - lung adenocarcinoma
OT  - postoperative recurrence survival
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/09/02 06:00
MHDA- 2017/09/02 06:01
PMCR- 2017/08/21
CRDT- 2017/09/02 06:00
PHST- 2017/09/02 06:00 [entrez]
PHST- 2017/09/02 06:00 [pubmed]
PHST- 2017/09/02 06:01 [medline]
PHST- 2017/08/21 00:00 [pmc-release]
AID - ott-10-4135 [pii]
AID - 10.2147/OTT.S136569 [doi]
PST - epublish
SO  - Onco Targets Ther. 2017 Aug 21;10:4135-4141. doi: 10.2147/OTT.S136569. 
      eCollection 2017.